Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2006.08.2305 on January 22 2007

Journal of Clinical Oncology, Vol 25, No 5 (February 10), 2007: pp. 571-578
© 2007 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Methods
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Juweid, M. E.
Right arrow Articles by Cheson, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Juweid, M. E.
Right arrow Articles by Cheson, B. D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

SPECIAL ARTICLE

Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

Malik E. Juweid, Sigrid Stroobants, Otto S. Hoekstra, Felix M. Mottaghy, Markus Dietlein, Ali Guermazi, Gregory A. Wiseman, Lale Kostakoglu, Klemens Scheidhauer, Andreas Buck, Ralph Naumann, Karoline Spaepen, Rodney J. Hicks, Wolfgang A. Weber, Sven N. Reske, Markus Schwaiger, Lawrence H. Schwartz, Josee M. Zijlstra, Barry A. Siegel, Bruce D. Cheson

From the Department of Radiology, University of Iowa, Iowa City, IA; Department of Nuclear Medicine, University Hospital Gasthuisberg, Leuven, Belgium; Departments of Hematology and Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, the Netherlands; Department of Nuclear Medicine, University of Ulm, Ulm; Department of Nuclear Medicine, University of Cologne, Cologne; Department of Nuclear Medicine, Technische Universitat Munchen, Munich; Department of Medicine, Dresden University of Technology, Dresden, Germany; Department of Oncology Services, Synarc Inc, San Francisco, CA; Department of Radiology, Mayo Clinic, Rochester, MN; Department of Radiology, Mount Sinai School of Medicine; Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY; Centre for Molecular Imaging, University of Melbourne, East Melbourne, Australia; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO; and the Department of Medicine, Georgetown University Hospital, Washington, DC

Address reprint requests to Malik Juweid, MD, at the University of Iowa, Department of Radiology, JPP 3859, 200 Hawkins Dr, Iowa City, IA 52242; e-mail: malik-juweid{at}uiowa.edu

Purpose To develop guidelines for performing and interpreting positron emission tomography (PET) imaging for treatment assessment in patients with lymphoma both in clinical practice and in clinical trials.

Methods An International Harmonization Project (IHP) was convened to discuss standardization of clinical trial parameters in lymphoma. An imaging subcommittee developed consensus recommendations based on published PET literature and the collective expertise of its members in the use of PET in lymphoma. Only recommendations subsequently endorsed by all IHP subcommittees were adopted.

Recommendations PET after completion of therapy should be performed at least 3 weeks, and preferably at 6 to 8 weeks, after chemotherapy or chemoimmunotherapy, and 8 to 12 weeks after radiation or chemoradiotherapy. Visual assessment alone is adequate for interpreting PET findings as positive or negative when assessing response after completion of therapy. Mediastinal blood pool activity is recommended as the reference background activity to define PET positivity for a residual mass ≥ 2 cm in greatest transverse diameter, regardless of its location. A smaller residual mass or a normal sized lymph node (ie, ≤ 1 x 1 cm in diameter) should be considered positive if its activity is above that of the surrounding background. Specific criteria for defining PET positivity in the liver, spleen, lung, and bone marrow are also proposed. Use of attenuation-corrected PET is strongly encouraged. Use of PET for treatment monitoring during a course of therapy should only be done in a clinical trial or as part of a prospective registry.

published online ahead of print at www.jco.org on January 22, 2007.

Presented in part at the 53rd Society of Nuclear Medicine Annual Meeting, June 3-7, 2006, San Diego, CA.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
P. Xie, J.-B. Yue, Z. Fu, R. Feng, and J.-M. Yu
Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma
Ann. Onc., November 13, 2009; (2009) mdp430v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
U. Petrausch, P. Samaras, P. Veit-Haibach, A. Tschopp, J. D. Soyka, A. Knuth, T. F. Hany, A. Mischo, C. Renner, and N. G. Schaefer
Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
Ann. Onc., November 13, 2009; (2009) mdp519v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. J. Sher, P. M. Mauch, A. Van Den Abbeele, A. S. LaCasce, J. Czerminski, and A. K. Ng
Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy
Ann. Onc., November 1, 2009; 20(11): 1848 - 1853.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. S. Hofman, N. C. Smeeton, S. C. Rankin, T. Nunan, and M. J. O'Doherty
Observer Variation in Interpreting 18F-FDG PET/CT Findings for Lymphoma Staging
J. Nucl. Med., October 1, 2009; 50(10): 1594 - 1597.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. Delbeke, S. Stroobants, E. de Kerviler, C. Gisselbrecht, M. Meignan, and P. S. Conti
Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma
Oncologist, October 1, 2009; 14(suppl_2): 30 - 40.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Bischof Delaloye, P. S. Conti, C. Gisselbrecht, and S. A. Gregory
Summary
Oncologist, October 1, 2009; 14(suppl_2): 52 - 54.
[Full Text] [PDF]

Home page
 JCOHome page
C. Furth, I. G. Steffen, H. Amthauer, J. Ruf, D. Misch, S. Schonberger, C. Kobe, T. Denecke, B. Stover, H. Hautzel, et al.
Early and Late Therapy Response Assessment With [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial
J. Clin. Oncol., September 10, 2009; 27(26): 4385 - 4391.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Markova, C. Kobe, M. Skopalova, K. Klaskova, K. Dedeckova, A. Plutschow, H. T. Eich, M. Dietlein, A. Engert, and T. Kozak
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value
Ann. Onc., July 1, 2009; 20(7): 1270 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Meignan, E. Itti, S. Bardet, J. Lumbroso, V. Edeline, P. Olivier, T. V. Borght, O. Reman, G. Karcher, O. Mundler, et al.
Development and Application of a Real-Time On-Line Blinded Independent Central Review of Interim Pet Scans to Determine Treatment Allocation in Lymphoma Trials
J. Clin. Oncol., June 1, 2009; 27(16): 2739 - 2741.
[Full Text] [PDF]

Home page
 RadiologyHome page
M. Picardi, A. Soricelli, F. Pane, P. Zeppa, E. Nicolai, M. De Laurentiis, F. Grimaldi, and B. Rotoli
Contrast-enhanced Harmonic Compound US of the Spleen to Increase Staging Accuracy in Patients with Hodgkin Lymphoma: A Prospective Study
Radiology, May 1, 2009; 251(2): 574 - 582.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber
Assessing Tumor Response to Therapy
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Hutchings and S. F. Barrington
PET/CT for Therapy Response Assessment in Lymphoma
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. Boellaard
Standards for PET Image Acquisition and Quantitative Data Analysis
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 11S - 20S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Terasawa, J. Lau, S. Bardet, O. Couturier, T. Hotta, M. Hutchings, T. Nihashi, and H. Nagai
Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review
J. Clin. Oncol., April 10, 2009; 27(11): 1906 - 1914.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Cheson
The Case Against Heavy PETing
J. Clin. Oncol., April 10, 2009; 27(11): 1742 - 1743.
[Full Text] [PDF]

Home page
 JNMHome page
E. Itti, C. Lin, J. Dupuis, G. Paone, D. Capacchione, A. Rahmouni, C. Haioun, and M. Meignan
Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy
J. Nucl. Med., April 1, 2009; 50(4): 527 - 533.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up
Haematologica, April 1, 2009; 94(4): 550 - 565.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Allen-Auerbach and W. A. Weber
Measuring Response with FDG-PET: Methodological Aspects
Oncologist, April 1, 2009; 14(4): 369 - 377.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Dupuis, E. Itti, A. Rahmouni, F. Hemery, C. Gisselbrecht, C. Lin, C. Copie-Bergman, K. Belhadj, T. El Gnaoui, I. Gaillard, et al.
Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
Ann. Onc., March 1, 2009; 20(3): 503 - 507.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
P. A. de Jong, H. M. Q. van Ufford, H.-J. Baarslag, M. J. de Haas, S. H. Wittebol, L. G. Quekel, and J. M. de Klerk
CT and 18F-FDG PET for Noninvasive Detection of Splenic Involvement in Patients with Malignant Lymphoma
Am. J. Roentgenol., March 1, 2009; 192(3): 745 - 753.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Ben-Haim and P. Ell
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
J. Nucl. Med., January 1, 2009; 50(1): 88 - 99.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl
18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy
J. Nucl. Med., January 1, 2009; 50(1): 8 - 17.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
L. Kostakoglu, D. J. Straus, H. Schoder, A. S. LaCasce, N. L Bartlett, N. Hall, J. L Johnson, S.-H. Jung, G. P. Canellos, L. H Schwartz, et al.
Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.
Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 1460 - 1460.
[Abstract]

Home page
 BloodHome page
C. Kobe, M. Dietlein, J. Franklin, J. Markova, A. Lohri, H. Amthauer, S. Klutmann, W. H. Knapp, J. M. Zijlstra, A. Bockisch, et al.
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Blood, November 15, 2008; 112(10): 3989 - 3994.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Suh, Y.-K. Kang, J.-L. Roh, M. R. Kim, J. S. Kim, J. Huh, J. H. Lee, Y. J. Jang, and B.-J. Lee
Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck
J. Nucl. Med., November 1, 2008; 49(11): 1783 - 1789.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. A. Jacobs, S. H. Swerdlow, J. Kant, K. A. Foon, R. Jankowitz, S. R. Land, N. DeMonaco, J. Joyce, J. L. Osborn, T. L. Evans, et al.
Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma
Clin. Cancer Res., November 1, 2008; 14(21): 7088 - 7094.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. R. Benz, M. S. Allen-Auerbach, F. C. Eilber, H. J.J. Chen, S. Dry, M. E. Phelps, J. Czernin, and W. A. Weber
Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas
J. Nucl. Med., October 1, 2008; 49(10): 1579 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K. Herrmann, F. Eckel, S. Schmidt, K. Scheidhauer, B. J. Krause, J. Kleeff, T. Schuster, H.-J. Wester, H. Friess, R. M. Schmid, et al.
In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors
J. Nucl. Med., September 1, 2008; 49(9): 1437 - 1444.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Mahner, S. Schirrmacher, W. Brenner, L. Jenicke, C. R. Habermann, N. Avril, and J. Dose-Schwarz
Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer
Ann. Onc., July 1, 2008; 19(7): 1249 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. J. Bishton, R. J. Hicks, D. A. Westerman, M. H. Prince, M. Wolf, and J. F. Seymour
A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy
Haematologica, May 1, 2008; 93(5): 789 - 790.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M. Crump, B. Coiffier, E. D. Jacobsen, L. Sun, J. L. Ricker, H. Xie, S. R. Frankel, S. S. Randolph, and B. D. Cheson
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
Ann. Onc., May 1, 2008; 19(5): 964 - 969.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
N. A. Mohile, L. M. DeAngelis, and L. E. Abrey
The utility of body FDG PET in staging primary central nervous system lymphoma
Neuro-oncol, April 1, 2008; 10(2): 223 - 228.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Dooms, E. Verbeken, S. Stroobants, K. Nackaerts, P. De Leyn, and J. Vansteenkiste
Prognostic Stratification of Stage IIIA-N2 Non-Small-Cell Lung Cancer After Induction Chemotherapy: A Model Based on the Combination of Morphometric-Pathologic Response in Mediastinal Nodes and Primary Tumor Response on Serial 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography
J. Clin. Oncol., March 1, 2008; 26(7): 1128 - 1134.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
C. Bodet-Milin, F. Kraeber-Bodere, P. Moreau, L. Campion, B. Dupas, and S. Le Gouill
Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma
Haematologica, March 1, 2008; 93(3): 471 - 472.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
C. Bodet-Milin, F. Kraeber-Bodere, B. Dupas, F. Morschhauser, T. Gastinne, S. Le Gouill, L. Campion, J.-L. Harousseau, W. A. Wegener, D. M. Goldenberg, et al.
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography
Haematologica, March 1, 2008; 93(3): 390 - 397.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
G. A. Ulaner, P. M. Colletti, and P. S. Conti
B-Cell Non-Hodgkin Lymphoma: PET/CT Evaluation after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy--Initial Experience
Radiology, March 1, 2008; 246(3): 895 - 902.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. C. Kwee, R. M. Kwee, and R. A. J. Nievelstein
Imaging in staging of malignant lymphoma: a systematic review
Blood, January 15, 2008; 111(2): 504 - 516.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya
Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment
Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 43 - 48.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. E. Juweid
18F-FDG PET as a Routine Test for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: Where Is the Evidence?
J. Nucl. Med., January 1, 2008; 49(1): 9 - 12.
[Full Text] [PDF]

Home page
 haematolHome page
C. Ansquer, T. Hervouet, A. Devillers, S. de Guibert, T. Gastinne, S. Le Gouill, E. Garin, A. Moreau, F. Kraeber-Bodere, and T. Lamy
18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease
Haematologica, January 1, 2008; 93(1): 128 - 131.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Tatsumi, J. H. Miller, and R. L. Wahl
18F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies
J. Nucl. Med., December 1, 2007; 48(12): 1923 - 1931.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. K. Schwarz, B. A. Siegel, F. Dehdashti, and P. W. Grigsby
Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma
JAMA, November 21, 2007; 298(19): 2289 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Seam, M. E. Juweid, and B. D. Cheson
The role of FDG-PET scans in patients with lymphoma
Blood, November 15, 2007; 110(10): 3507 - 3516.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
J. Nucl. Med., November 1, 2007; 48(11): 1767 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber
18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative?
J. Nucl. Med., October 1, 2007; 48(10): 1580 - 1582.
[Full Text] [PDF]

Home page
 Ann OncolHome page
S. Kako, K. Izutsu, Y. Ota, Y. Minatani, M. Sugaya, T. Momose, K. Ohtomo, Y. Kanda, S. Chiba, T. Motokura, et al.
FDG-PET in T-cell and NK-cell neoplasms
Ann. Onc., October 1, 2007; 18(10): 1685 - 1690.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani, J. Dupuis, G. Paone, J.-N. Talbot, A. Rahmouni, and M. Meignan
Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis
J. Nucl. Med., October 1, 2007; 48(10): 1626 - 1632.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Gallamini, M. Hutchings, L. Rigacci, L. Specht, F. Merli, M. Hansen, C. Patti, A. Loft, F. Di Raimondo, F. D'Amore, et al.
Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
J. Clin. Oncol., August 20, 2007; 25(24): 3746 - 3752.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn
Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond
Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Herrmann, H. A. Wieder, A. K. Buck, M. Schoffel, B.-J. Krause, F. Fend, T. Schuster, C. Meyer zum Buschenfelde, H.-J. Wester, J. Duyster, et al.
Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma
Clin. Cancer Res., June 15, 2007; 13(12): 3552 - 3558.
[Abstract] [Full Text] [PDF]

Home page
 JWatch Oncology and HematologyHome page
Revised Lymphoma Response Criteria
Journal Watch Oncology and Hematology, February 16, 2007; 2007(216): 2 - 2.
[Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online